Phathom Pharmaceuticals, Inc. EPS (Basic, from Continuous Ops)

EPS (Basic, from Continuous Ops) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic, from Continuous Ops) growth rates and interactive chart.


Highlights and Quick Summary

  • EPS (Basic, from Continuous Ops) for the quarter ending September 29, 2021 was -0.98 (a -1.48% decrease compared to previous quarter)
  • Year-over-year quarterly EPS (Basic, from Continuous Ops) decreased by -38.66%
  • Annual EPS (Basic, from Continuous Ops) for 2020 was -3.88 (a -82.69% decrease from previous year)
  • Annual EPS (Basic, from Continuous Ops) for 2019 was -22.44 (a 10447.42% increase from previous year)
  • Twelve month EPS (Basic, from Continuous Ops) ending September 29, 2021 was -4.54 (a -0.86% decrease compared to previous quarter)
  • Twelve month trailing EPS (Basic, from Continuous Ops) increased by 16.96% year-over-year
Trailing EPS (Basic, from Continuous Ops) for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-4.54 -4.58 -4.22 -3.88
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic, from Continuous Ops) of Phathom Pharmaceuticals, Inc.

Most recent EPS (Basic, from Continuous Ops)of PHAT including historical data for past 10 years.

Interactive Chart of EPS (Basic, from Continuous Ops) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EPS (Basic, from Continuous Ops) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.98 -1.0 -0.96
2020 -1.6 -1.02 -0.64 -0.62 -3.88
2019 0.15 -9.3 -13.11 -0.19 -22.44
2018 -0.04 -0.21

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.